HENN MATTHEW R (Chief Scientific Officer) sold 1.0% of their position (77.00 shares) of SERES THERAPEUTICS, INC. on the open market
Open‑market sale worth $579.81 — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 5/19/2026ACC: 0001193125-26-230727
Officer· Chief Scientific Officer
Since Feb 2019
-77.00
Net shares
Net seller
$579.81
Total sold
1
Open market trades
0B · 1S
4
Total transactions
238.00 acquired · 315.00 disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+238.00
Price / share
—
Trade value
—
% of position
3.1%
5/15/2026
7.68K→7.92K
Common Stock
Direct
Shares
−77.00
Price / share
$7.53
Trade value
$579.81
% of position
1.0%
5/18/2026
7.92K→7.84K
Total
Net shares
+161.00
Net value
-$579.81
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/15/2026 | M · Option Exercise | +238.00 | — | — | 3.1% | 7.68K | 7.92K |
| Common Stock Direct | 5/18/2026 | S · Sale | −77.00 | $7.53 | $579.81 | 1.0% | 7.92K | 7.84K |
| Total | +161.00 | -$579.81 | ||||||
Derivative Transactions2
Restricted Stock Units
Direct
Converts to
Common Stock
141.00 shares
Shares
−141.00
Strike price
Held after
422.00
Exercisable
—
5/15/2026
Restricted Stock Units
Direct
Converts to
Common Stock
97.00 shares
Shares
−97.00
Strike price
Held after
683.00
Exercisable
—
5/15/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Stock141.00 shares | 5/15/2026 | M · Option Exercise | −141.00 | — | 422.00 | |
| Restricted Stock Units Direct | Common Stock97.00 shares | 5/15/2026 | M · Option Exercise | −97.00 | — | 683.00 |